Atovaquon/Proguanilhydrochloride Glenmark

Atovaquone/Proguanil Hydrochloride Glenmark is a combination medication used to prevent and treat malaria. This oral medication is manufactured by Glenmark Arzneimittel Gmbh and is suitable for oral use.

Atovaquone/Proguanil Hydrochloride Glenmark is primarily used for the prevention and treatment of malaria, a mosquito-borne disease caused by parasites. It works by interfering with the growth of parasites in the red blood cells. This medication is often prescribed for travelers to areas where malaria is common, helping to protect against the disease. It is also used to treat active malaria infections, providing relief from symptoms and aiding in recovery.

Common effects of Atovaquone/Proguanil Hydrochloride Glenmark may include nausea, vomiting, diarrhea, and stomach pain. Some users might experience headache, dizziness, or cough. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare professional.

Atovaquone/Proguanil Hydrochloride Glenmark should be used with caution in individuals with severe kidney or liver problems. It is important to follow the prescribed dosage and complete the full course of treatment to ensure effectiveness. This medication should be stored at room temperature and kept out of reach of children.

Atovaquone/Proguanil Hydrochloride Glenmark may interact with certain medications, including antacids, metoclopramide, and drugs that affect liver enzymes. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be limited while using this medication.